First Tracks Biotherapeutics, Inc.

424B3 priced

10,497,054 shares

EFFECT effective

S-1 filed

10,497,054 shares · Gross proceeds $0.00

First Tracks Biotherapeutics, Inc. became a separate public company following a spin-off from AnaptysBio, Inc. on April 20, 2026. The S-1 filing relates to the resale of 10,497,054 shares of common stock by selling stockholders, with no proceeds going to the company. The company is listed on Nasdaq under 'TRAX' and is categorized as an emerging growth company and smaller reporting company.

DRS filed

First Tracks Biotherapeutics, Inc. has transitioned from a subsidiary of AnaptysBio, Inc. to an independent public company following a Spin-Off on April 20, 2026. The current DRS filing relates to a prospectus for the resale of up to 10,497,054 shares of common stock by selling stockholders, with no proceeds going to the company. The company is now listed on Nasdaq under the symbol 'TRAX' and qualifies as an emerging growth company and smaller reporting company.

CERT inactive

The current filing for First Tracks Biotherapeutics, Inc. is a CERT form dated 2026-04-01, succeeding a previous DRS form. The filing appears to relate to a securities registration, likely in preparation for an IPO, but the text content is non-readable or corrupted, limiting actionable insights. The previous DRS filing for a related entity (Biopharma Company, Inc.) included standard registration details, risk factors, and financial disclosures, but no direct comparability can be confirmed due to formatting issues and lack of visible content in the current filing.

DRS filed

First Tracks Biotherapeutics, Inc. (formerly Biopharma Company, Inc.) has submitted a confidential DRS filing for an upcoming IPO, indicating a spin-off from AnaptysBio, Inc. The registration statement remains non-public, with details incorporated by reference from an information statement. The company is classified as a smaller reporting company and emerging growth company, with no prior filings noted. Key focus areas include biopharmaceutical development and operational transitions following the spin-off.